Cellectis (NASDAQ:CLLS) Share Price Crosses Above Fifty Day Moving Average - What's Next?

Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.49 and traded as high as $1.65. Cellectis shares last traded at $1.59, with a volume of 37,406 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CLLS shares. Wall Street Zen cut Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays decreased their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th.

Cellectis Stock Performance

The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.44. The stock's fifty day moving average is $1.49 and its two-hundred day moving average is $1.48. The firm has a market capitalization of $88.09 million, a price-to-earnings ratio of -1.84 and a beta of 2.91.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The firm had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative net margin of 114.82% and a negative return on equity of 62.55%. On average, analysts predict that Cellectis S.A. will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

A number of hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 26,461 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after purchasing an additional 3,284,409 shares during the period. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares during the last quarter. OLD Mission Capital LLC acquired a new position in shares of Cellectis in the first quarter valued at $31,000. Finally, Millennium Management LLC bought a new position in shares of Cellectis in the fourth quarter valued at about $962,000. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.